Which GLP-1 is Approved for Weight Loss: Understanding the Current Landscape

Last reviewed: June 3, 2026

Last updated: June 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The FDA has approved semaglutide, tirzepatide, and other GLP-1 receptor agonists specifically for weight loss in adults with obesity or overweight with weight-related conditions. These medications activate receptors in the brain that control hunger and blood sugar, leading to reduced calorie intake and sustainable weight reduction. Knowing the landscape of approved options empowers you to discuss the best choice with your healthcare provider.

FDA-Approved GLP-1 Medications for Weight Loss

The U.S. Food and Drug Administration has approved multiple GLP-1 receptor agonists for chronic weight management. Semaglutide (marketed as Wegovy for weight loss) received FDA approval in 2021 and has demonstrated an average weight loss of 15% body weight in clinical trials. Tirzepatide, a dual GIP/GLP-1 receptor agonist, was approved by the FDA in 2023 and showed even greater weight reduction, with some patients losing over 20% of their body weight. These approvals represent a significant advancement in obesity treatment, offering patients medically supervised options backed by rigorous clinical research.

Beyond injectable forms, the FDA has also approved oral versions of these medications for weight management. Oral semaglutide (Rybelsus) offers patients who prefer tablets an alternative to injections, though absorption requirements may affect consistency. Both injectable and oral formulations work through the same biological mechanisms, targeting appetite centers and improving metabolic function. The choice between injection and oral delivery depends on individual preference, lifestyle, and medical circumstances that your provider can assess.

How Semaglutide Works for Weight Loss

Semaglutide mimics glucagon-like peptide-1, a natural hormone that regulates appetite and blood sugar levels. When semaglutide activates GLP-1 receptors in the brain, it signals fullness and reduces hunger cravings, leading most patients to eat substantially less without feeling deprived. The medication also slows gastric emptying, meaning food stays in your stomach longer and you feel satisfied with smaller portions. Clinical data shows that patients on semaglutide maintain weight loss as long as they continue the medication, making it a sustainable tool for long-term management.

Beyond appetite suppression, semaglutide influences how your body processes glucose and stores fat. It improves insulin sensitivity, helping regulate blood sugar fluctuations that often trigger overeating and cravings. For many patients, these metabolic improvements create a foundation for lasting behavioral change and healthier eating patterns. Understanding this dual action—appetite reduction plus metabolic support—explains why GLP-1 therapy has proven effective for people who struggled with diet and exercise alone.

Tirzepatide vs. Semaglutide: Key Differences

While both semaglutide and tirzepatide are FDA-approved GLP-1 medications, tirzepatide is technically a dual GIP/GLP-1 receptor agonist, meaning it activates two different appetite-control pathways simultaneously. In head-to-head trials, tirzepatide produced greater average weight loss than semaglutide—approximately 22% compared to 15%—though individual results vary based on genetics, lifestyle, and adherence. Tirzepatide was also approved more recently, arriving on the market in 2023 with data from larger, longer-running clinical studies. Both medications are available in injectable and oral forms, giving patients flexibility in how they receive treatment.

The choice between these two medications depends on personal factors including your baseline weight, health goals, tolerance for side effects, and genetic predisposition to GLP-1 pathway activation. Some patients respond exceptionally well to semaglutide, while others achieve better results with tirzepatide's dual-action mechanism. This is where personalized medicine becomes valuable—genetic testing can reveal your peptide pathway variations and help predict which medication may work best for your unique biology. PlexusDx offers the Precision Peptide Genetic Test to identify these individual variations and guide your medication selection.

Accessing FDA-Approved GLP-1 Therapy at PlexusDx

PlexusDx provides access to compounded semaglutide and tirzepatide from licensed 503A compounding pharmacies, making these proven medications available without insurance requirements or membership fees. Whether you choose injections or oral formulations, PlexusDx offers consistent monthly pricing—your dose may need to go up as you progress through treatment, but your monthly cost stays the same. Compounded semaglutide injections start at $149 per month, while compounded tirzepatide injections begin at $249 per month across all dosage tiers. HSA and FSA accounts are eligible for these purchases, improving affordability for qualifying patients.

The process begins with a consultation to assess your medical history, weight-loss goals, and current medications. PlexusDx clinicians work with you to determine whether semaglutide, tirzepatide, or PlexusDx's proprietary GLP-Squared dual-compound formula best matches your needs. After your first month of treatment, you have the option to add the Precision Peptide Genetic Test for $99, which analyzes your genetic variations in GLP1R, GIPR, FTO, and MC4R pathways to optimize future medication decisions. This data-driven approach ensures you receive personalized therapy backed by both FDA-approved science and your individual genetic profile.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide the same as FDA-approved Wegovy?

Compounded semaglutide contains the same active ingredient as Wegovy and works identically in the body. The difference is that compounded versions are prepared by licensed 503A pharmacies under FDA regulation, rather than by a branded pharmaceutical manufacturer. PlexusDx sources all compounded medications from licensed 503A compounding pharmaci...

What weight loss results can I expect from semaglutide?

Clinical trials show that patients on semaglutide lose an average of 15% of their body weight over 68 weeks, with some individuals achieving greater losses. Results depend on dose, adherence, diet quality, physical activity, and individual metabolism. Most patients notice reduced appetite within 2-4 weeks and measurable weight loss within 8-12 w...

How much does semaglutide cost at PlexusDx?

PlexusDx's compounded semaglutide injection starts at $149 per month, flat across all dosage levels—meaning your price remains the same whether you're at the starting dose or a higher maintenance dose. The medication is available without insurance or membership fees, and both HSA and FSA accounts can be used for payment. Oral semaglutide is also...

Are there side effects from GLP-1 medications like semaglutide?

Common side effects include nausea, vomiting, constipation, and reduced appetite, though most are mild and temporary as your body adjusts. Serious side effects are rare but can include pancreatitis or allergic reactions—report any severe abdominal pain or difficulty breathing to your provider immediately. Most patients find side effects manageab...

Can the Precision Peptide Genetic Test help me choose between semaglutide and tirzepatide?

Yes. The PlexusDx Precision Peptide Genetic Test analyzes your variations in the GLP1R, GIPR, FTO, and MC4R genes—key pathways that determine how effectively you'll respond to GLP-1 therapy and dual-agonist therapy. Patients with certain GLP1R variants may achieve superior results with semaglutide, while those with specific GIPR variants often r...

Related Reading

• Glp 1 For Weight Loss 2
• Glp 1 Weight Loss Before And After
• Glp 1 Dosage For Weight Loss
• Glp 1 Receptor Agonist For Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.